{"schema_version":"secwatch.filing_event.v1","accession":"0001628280-26-033859","form_type":"8-K","ticker":"OVID","cik":"0001636651","company_name":"Ovid Therapeutics Inc.","filed_at":"2026-05-12T11:04:29+00:00","discovered_at":"2026-05-12T11:05:00.252128+00:00","generated_at":"2026-05-12T11:05:26.175530+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Ovid Q1 net loss $17M; raises $60M PIPE; dosed first OV4071 Phase 1; OV329 Phase 2 planned","bullets":["Q1 2026 net loss of $17.0M ($0.12/share) vs $10.2M loss ($0.14) in Q1 2025.","Cash $165.6M as of Mar 31, 2026; plus $27.3M in April from warrant exercises; runway into 2029.","Dosed first healthy volunteer in Phase 1 study of OV4071, oral KCC2 direct activator, for psychosis.","OV329 shows favorable safety/PK up to 9 mg; Phase 2 for focal onset seizures and TSC/infantile spasms planned.","Raised $60.0M gross from March 2026 PIPE and $53.9M from Series A warrant exercises (Oct 2025 PIPE)."],"urls":{"canonical":"https://secwatch.observer/filing/0001628280-26-033859","json":"https://secwatch.observer/filing/0001628280-26-033859.json","markdown":"https://secwatch.observer/filing/0001628280-26-033859.md","text":"https://secwatch.observer/filing/0001628280-26-033859.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1636651/000162828026033859/0001628280-26-033859-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1636651/000162828026033859/ovid-20260512.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-12T11:05:26.175530+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"632cd982ab821e3354e0c2f89f76eca678075706","claim":"Ovid Therapeutics Inc. reported financial results for first quarter ended March 31, 2026.","evidence_excerpt":"On May 12, 2026, Ovid Therapeutics Inc. (the “Company”) issued a press release announcing business updates and first quarter 2026 financial results.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1636651/000162828026033859/0001628280-26-033859-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"first quarter ended March 31, 2026"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}